Cargando…
Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy
ELAC2 is a ubiquitously expressed enzyme potentially involved in tRNA processing and cell signaling pathways. Mutations of the ELAC2 gene have been found to confer increased prostate cancer susceptibility in families. ELAC2 protein expression was analyzed by immunohistochemistry in 9,262 patients an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697635/ https://www.ncbi.nlm.nih.gov/pubmed/31452838 http://dx.doi.org/10.18632/oncotarget.27132 |
_version_ | 1783444403265732608 |
---|---|
author | Schroeder, Cornelia Navid-Hill, Elham Meiners, Jan Hube-Magg, Claudia Kluth, Martina Makrypidi-Fraune, Georgia Simon, Ronald Büscheck, Franziska Luebke, Andreas M. Goebel, Cosima Lang, Dagmar S. Weidemann, Sören Neubauer, Emily Hinsch, Andrea Jacobsen, Frank Lebok, Patrick Michl, Uwe Pehrke, Dirk Huland, Hartwig Graefen, Markus Schlomm, Thorsten Sauter, Guido Höflmayer, Doris |
author_facet | Schroeder, Cornelia Navid-Hill, Elham Meiners, Jan Hube-Magg, Claudia Kluth, Martina Makrypidi-Fraune, Georgia Simon, Ronald Büscheck, Franziska Luebke, Andreas M. Goebel, Cosima Lang, Dagmar S. Weidemann, Sören Neubauer, Emily Hinsch, Andrea Jacobsen, Frank Lebok, Patrick Michl, Uwe Pehrke, Dirk Huland, Hartwig Graefen, Markus Schlomm, Thorsten Sauter, Guido Höflmayer, Doris |
author_sort | Schroeder, Cornelia |
collection | PubMed |
description | ELAC2 is a ubiquitously expressed enzyme potentially involved in tRNA processing and cell signaling pathways. Mutations of the ELAC2 gene have been found to confer increased prostate cancer susceptibility in families. ELAC2 protein expression was analyzed by immunohistochemistry in 9,262 patients and Kaplan-Meier curves of PSA recurrence-free survival were calculated in 8,513 patients treated with radical prostatectomy. Nuclear ELAC2 staining was observed in 60.8% of prostate cancers. It was weak in 26.3%, moderate in 26.6% and strong in 7.9%. Strong nuclear ELAC2 expression was associated with advanced tumor stage, nodal metastasis, higher Gleason grade, presence of TMPRSS2:ERG fusion, higher Ki67-labeling index and PTEN deletion. The difference in 1-, 5- and 10-year recurrence-free survival between strong and weak nuclear ELAC2 intensity is 7.2/13.8/17.6% in all cancers, 7.4/16.1/26.5% in the ERG negative subset, and 3.1/5.7/9.8% in the ERG positive subset. Regarding the univariate hazard ratio, PSA recurrence-free survival after prostatectomy for strong nuclear ELAC2 expression is 1.89 (1.64–2.10, p < 0.0001). It is independent of preoperative PSA-level, Gleason grade, pathological stage, surgical margin stage, and lymph node stage (multivariate hazard ratio 1.29 (1.11–1.49, p = 0.001). We conclude that nuclear ELAC2 expression is an independent prognostic marker for PSA recurrence-free survival after radical prostatectomy with a weak to moderate increase of the hazard ratio for biochemical relapse. |
format | Online Article Text |
id | pubmed-6697635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-66976352019-08-26 Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy Schroeder, Cornelia Navid-Hill, Elham Meiners, Jan Hube-Magg, Claudia Kluth, Martina Makrypidi-Fraune, Georgia Simon, Ronald Büscheck, Franziska Luebke, Andreas M. Goebel, Cosima Lang, Dagmar S. Weidemann, Sören Neubauer, Emily Hinsch, Andrea Jacobsen, Frank Lebok, Patrick Michl, Uwe Pehrke, Dirk Huland, Hartwig Graefen, Markus Schlomm, Thorsten Sauter, Guido Höflmayer, Doris Oncotarget Research Paper ELAC2 is a ubiquitously expressed enzyme potentially involved in tRNA processing and cell signaling pathways. Mutations of the ELAC2 gene have been found to confer increased prostate cancer susceptibility in families. ELAC2 protein expression was analyzed by immunohistochemistry in 9,262 patients and Kaplan-Meier curves of PSA recurrence-free survival were calculated in 8,513 patients treated with radical prostatectomy. Nuclear ELAC2 staining was observed in 60.8% of prostate cancers. It was weak in 26.3%, moderate in 26.6% and strong in 7.9%. Strong nuclear ELAC2 expression was associated with advanced tumor stage, nodal metastasis, higher Gleason grade, presence of TMPRSS2:ERG fusion, higher Ki67-labeling index and PTEN deletion. The difference in 1-, 5- and 10-year recurrence-free survival between strong and weak nuclear ELAC2 intensity is 7.2/13.8/17.6% in all cancers, 7.4/16.1/26.5% in the ERG negative subset, and 3.1/5.7/9.8% in the ERG positive subset. Regarding the univariate hazard ratio, PSA recurrence-free survival after prostatectomy for strong nuclear ELAC2 expression is 1.89 (1.64–2.10, p < 0.0001). It is independent of preoperative PSA-level, Gleason grade, pathological stage, surgical margin stage, and lymph node stage (multivariate hazard ratio 1.29 (1.11–1.49, p = 0.001). We conclude that nuclear ELAC2 expression is an independent prognostic marker for PSA recurrence-free survival after radical prostatectomy with a weak to moderate increase of the hazard ratio for biochemical relapse. Impact Journals LLC 2019-08-13 /pmc/articles/PMC6697635/ /pubmed/31452838 http://dx.doi.org/10.18632/oncotarget.27132 Text en Copyright: © 2019 Schroeder et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Schroeder, Cornelia Navid-Hill, Elham Meiners, Jan Hube-Magg, Claudia Kluth, Martina Makrypidi-Fraune, Georgia Simon, Ronald Büscheck, Franziska Luebke, Andreas M. Goebel, Cosima Lang, Dagmar S. Weidemann, Sören Neubauer, Emily Hinsch, Andrea Jacobsen, Frank Lebok, Patrick Michl, Uwe Pehrke, Dirk Huland, Hartwig Graefen, Markus Schlomm, Thorsten Sauter, Guido Höflmayer, Doris Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy |
title | Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy |
title_full | Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy |
title_fullStr | Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy |
title_full_unstemmed | Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy |
title_short | Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy |
title_sort | nuclear elac2 overexpression is associated with increased hazard for relapse after radical prostatectomy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697635/ https://www.ncbi.nlm.nih.gov/pubmed/31452838 http://dx.doi.org/10.18632/oncotarget.27132 |
work_keys_str_mv | AT schroedercornelia nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT navidhillelham nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT meinersjan nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT hubemaggclaudia nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT kluthmartina nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT makrypidifraunegeorgia nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT simonronald nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT buscheckfranziska nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT luebkeandreasm nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT goebelcosima nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT langdagmars nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT weidemannsoren nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT neubaueremily nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT hinschandrea nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT jacobsenfrank nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT lebokpatrick nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT michluwe nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT pehrkedirk nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT hulandhartwig nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT graefenmarkus nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT schlommthorsten nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT sauterguido nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy AT hoflmayerdoris nuclearelac2overexpressionisassociatedwithincreasedhazardforrelapseafterradicalprostatectomy |